Abstract
Cholinergic deficit is a cardinal feature of Alzheimers disease, and cholinesterase inhibitors represent one of the most prominent means of mitigating this dysfunction. Cholinesterase inhibitors provide mild symptomatic relief, although they lose their efficacy over time most likely because they are not disease-modifying agents. An alternative strategy for restoring cholinergic function and attenuating the cognitive decline involves acting on the receptors on which acetylcholine acts. Stimulation of muscarinic acetylcholine receptors and in particular the M1 subtype has been shown to have a beneficial effect in restoring cognition in patients with Alzheimers disease and in attenuating Aβ and tau pathology in different animal models. In this review, we discuss the role of M1 agonists as a potential disease – modifying therapy for Alzheimers disease.
Keywords: M1 Agonists, Alzheimer's disease, cholinesterase inhibitors, acetylcholine receptors, cholinergic neurons
Current Alzheimer Research
Title: M1 Agonists as a Potential Disease-Modifying Therapy for Alzheimers Disease
Volume: 6 Issue: 2
Author(s): Antonella Caccamo, Abraham Fisher and Frank M. LaFerla
Affiliation:
Keywords: M1 Agonists, Alzheimer's disease, cholinesterase inhibitors, acetylcholine receptors, cholinergic neurons
Abstract: Cholinergic deficit is a cardinal feature of Alzheimers disease, and cholinesterase inhibitors represent one of the most prominent means of mitigating this dysfunction. Cholinesterase inhibitors provide mild symptomatic relief, although they lose their efficacy over time most likely because they are not disease-modifying agents. An alternative strategy for restoring cholinergic function and attenuating the cognitive decline involves acting on the receptors on which acetylcholine acts. Stimulation of muscarinic acetylcholine receptors and in particular the M1 subtype has been shown to have a beneficial effect in restoring cognition in patients with Alzheimers disease and in attenuating Aβ and tau pathology in different animal models. In this review, we discuss the role of M1 agonists as a potential disease – modifying therapy for Alzheimers disease.
Export Options
About this article
Cite this article as:
Caccamo Antonella, Fisher Abraham and LaFerla M. Frank, M1 Agonists as a Potential Disease-Modifying Therapy for Alzheimers Disease, Current Alzheimer Research 2009; 6 (2) . https://dx.doi.org/10.2174/156720509787602915
DOI https://dx.doi.org/10.2174/156720509787602915 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Alzheimer's Disease Drug Development
Alzheimer's disease is a progressive neurodegenerative disorder that affects millions of people worldwide. Despite decades of research, no cure or disease-modifying treatment is available yet. Therefore, the need for developing effective therapies to treat Alzheimer's disease is an urgent matter. This special issue aims to provide a comprehensive overview of ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
(Commentary [Research Highlights] A Toll Road to Alzheimer Disease?)
CNS & Neurological Disorders - Drug Targets Altered Arginine Metabolism in Cells Transfected with Human Wild-Type Beta Amyloid Precursor Protein (βAPP)
Current Alzheimer Research Enhancing the Delivery of Anti Retroviral Drug “Saquinavir” Across the Blood Brain Barrier Using Nanoparticles
Current HIV Research HIV-1 Latency and Eradication: Past, Present and Future
Current HIV Research Peripheral Chemo-Cytokine Profiles in Alzheimers and Parkinsons Diseases
Mini-Reviews in Medicinal Chemistry Functional Roles of Synaptic and Extrasynaptic NMDA Receptors in Physiological and Pathological Neuronal Activities
Current Drug Targets Mitochondrion-Specific Antioxidants as Drug Treatments for Alzheimer Disease
CNS & Neurological Disorders - Drug Targets Recent Advances in the Medicinal Chemistry of Sodium Channel Blockers and their Therapeutic Potential
Current Topics in Medicinal Chemistry Alzheimer’s Disease-like Early-phase Brain Pathogenesis: Self-curing Amelioration of Neurodegeneration from Pro-inflammatory ‘Wounding’ to Anti-inflammatory ‘Healing’
Current Alzheimer Research Selectivity Problems with Drugs Acting on Cardiac Na<sup>+</sup> and Ca<sup>2+</sup> Channels
Current Medicinal Chemistry Protein Conformational Diseases: From Mechanisms to Drug Designs
Current Drug Discovery Technologies Genetic Surgery - A Right Strategy to Attack Cancer
Current Gene Therapy Crossed Cerebellar Diaschisis in Alzheimer’s Disease
Current Alzheimer Research Progression of Alzheimer-type Neurofibrillary Tangles is Related to the Proximodistal Segments of the Hemispheric Arteries
Current Alzheimer Research The Association of Folic Acid Deficiency and Diabetic Nephropathy in Patients with Type 2 Diabetes Mellitus
Endocrine, Metabolic & Immune Disorders - Drug Targets High Sensitivity C-Reactive Protein (hsCRP): A New Biochemical Marker of Atherosclerotic Vascular Disease
Current Cardiology Reviews Recent Progress Toward Hydrogen Medicine: Potential of Molecular Hydrogen for Preventive and Therapeutic Applications
Current Pharmaceutical Design Evaluation of Pharmacological Treatment Strategies in Traumatic Brain Injury
Current Pharmaceutical Design Proposing a “Lipemic Index” As a Nutritional and Research Tool
Current Vascular Pharmacology Imaging of Muscarinic Receptors in the Central Nervous System
Current Pharmaceutical Design